FDA approves first PSMA PET imaging agent for prostate cancer
US FDA approves the Piflufolastat F-18 injection for prostate cancer detection It is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA commercially available PSMA PET imaging agent. It allows doctors to see suspected prostate cancer at an early stage.
This is a highly effective imaging approach to detect the spread of cancer to other parts of the body.
Read the full article: